Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Principia nets $197.4mm through public offering

Executive Summary

Principia Biopharma Inc. (treatments for immune mediated diseases) netted $197.4mm through a public offering of 7.5mm common shares at $28. The company is using its Tailored Covalency technology to design therapies that have the potency, selectivity, and safety of injectable drugs but are in pill form. Offering proceeds will support pipeline development, working capital, and corporate needs.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies